Background. The use of dried blood spots (DBS) for HIV1 viral load quantification can greatly improve access to viral monitoring for HIVinfected patients receiving treatment in resourcelimited settings. Objectives. To evaluate and validate HIV viral load measurement from DBS in subSaharan Africa, with a reliable, allautomated, standard commercial assay such as the Abbott m2000. Methods. A total of 277 DBS were collected in different health centres in Malawi and Mozambique and analysed for viral load determination using the Abbott m2000 assay with the corresponding plasma samples as gold standard. Samples were extracted using the m2000SP automatic extractor and then processed as the plasma samples using the specific 1.0 mL HIVRNA DBS protocol. Results. Among samples with detectable HIVRNA the correlation between viral load obtained from the paired 131 plasma and DBS samples was high (r=0.946). Overall, viral load values between DBS and plasma differed by less than 0.5 log unit in 90.1% of cases and by less than 1 log unit in 100% of cases. Using a threshold of 1 000 copies/mL (defining virological failure in resourcelimited settings), sensitivity was 94.2% and specificity 98.6%, and both positive and negative predictive values were high (98.5% and 94.5%, respectively). Conclusion. DBS extracted and processed using the Abbott automated system can be reliably used in resourcelimited setting to diagnose virological failure.
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The use of dried blood spots (DBS) has greatly facili tated genetic and metabolic screening of newborns by simplifying sample collection, storage and transport. Measuring the HIV1 burden from whole blood dried on filter paper provides a suitable alternative for low technology settings with limited access to laboratory facilities, such as sub Saharan Africa (SSA). Nucleic acids in DBS have been shown to be stable for several months at room temperature, provided the DBS specimens are thoroughly dried and are stored with desiccant. [14] DBS specimens can therefore be collected at remote rural sites and transported to a central or regional testing laboratory without refrigeration. DBS are userfriendly and costeffective in resourcelimited settings, their ability being demon strated to correctly identify virological failure.
[57] DBS use may therefore represent a paradigm shift in accessibility to virological testing for HIV infection. Indeed, the Diagnostic Access Initiative (http://www.unaids.org) signed in Melbourne during the 20th International AIDS Conference in July 2014, specifically focused on ensuring that all people accessing HIV treatment should have ready access to tests that monitor levels of the virus in their bodies, and underlined the importance of developing new and affordable viral load and early infant diagnosis technology.
The objective of this study was to evaluate and validate, in SSA, HIV viral load measurement from DBS with a reliable, allautomated, standard commercial assay, the Abbott m2000 (Abbott Molecular, USA). The study was performed in two healthcare settings in two different countries, Malawi and Mozambique, within the health centre network of the DREAM (Drug Resource Enhancement against AIDS and Malnutrition) Programme of the Community of Sant'Egidio. Briefly, DREAM is a holistic programme started in December 2001 for the care of people living with HIV and the prevention of mothertochild transmission (http://dream. santegidio.org). To date, the DREAM programme is active in ten countries (Mozambique, Malawi, Tanzania, Kenya, Republic of Guinea, Guinea Bissau, Cameroon, Democratic Republic of Congo, Angola and Nigeria) in SSA, with a network of 42 health centres and 20 laboratories. Because of the hub infrastructure used for health centres and laboratories in every country, only those facilities with molecular biology laboratories perform the HIV viral load testing. The possibility of using DBS to deliver samples for HIV viral load may therefore increase the accessibility to the test in rural areas and small settings. In this study, results were analysed according to different thresholds of HIVRNA in order to develop an HIV viral load testing procedure from DBS that could be implemented in SSA. Eight hundred microlitres of plasma were used to extract nucleic acids with the Abbott automatic extractor, Sample Preparation System (m2000SP). The nucleic acids extracted by m2000SP were used for realtime amplification with the Abbott m2000RT using the 0.6 mL HIVRNA protocol. DBS (50 µL of peripheral blood per spot) were airdried overnight and stored in a plastic bag with desiccant at room temperature. DBS eluate was obtained by incubating two of five spots for each sample with 1.7 mL of Abbot Bulk lysis buffer for 15 minutes at room temperature with constant mixing. The eluate was transferred to a test tube and extracted using the m2000SP automatic extractor with the 1.0 mL HIV1 RNA DBS Exp V04 protocol. The extracted material was then quantitated as the plasma samples with the realtime PCR Abbott m2000RT using the corresponding 1 mL DBS protocol, according to the manufacturer's instructions.
Methods
All HIVRNA values were log 10 transformed before analysis. Results reported as not detected and below detection limit (<40 copies/mL) were analysed considering a value of 1.6 log 10 HIVRNA per mL. Results were expressed as means and standard deviations (SDs). Viral load measured in DBS and paired plasma samples were compared by the Pearson correlation analysis. The BlandAltman method [8] was used for analysis of concordance between the results obtained from plasma and those obtained from DBS. Statistical analysis was done using SPSS version 22 (IBM, USA).
Results
A total of 277 paired plasma and DBS samples were analysed. Samples were divided according to the HIVRNA level in plasma: ≤2 log 10 (n=109), 2 log 10 (range 2.11 2.99; n=30), 3 log 10 (range 3.10 3.99; n=81), 4 log 10 (range 4.04 4.96; n=29) and ≥5 log 10 (range 5.03 6.84; n=28). Samples were analysed after a mean time of 1 week after collection and storage (at room temperature).
Agreement between detectable and undetectable viral load for plasma and DBS was seen in 83.0% of cases. In 16.6% of cases (n=46), HIVRNA was not detectable in DBS while measurable levels were present in plasma (between 1.76 and 3.83 logs; mean 2.48). One DBS gave a result of 3.54 log 10 while the corresponding plasma level was <1.6 log 10 . In all other cases of undetectable viral load in plasma (n=99), HIVRNA was not detectable in DBS. The lowest HIVRNA level detected by DBS was 616 copies/mL.
Using the 40 copies/mL threshold, the test had relatively good sensitivity (74%), high specificity (99%) and a high positive predictive value (99.2%) ( Table 1) . Negative predictive value was low (68.3%) as an effect of the low rate of detection when plasma HIVRNA was below 3 log copies/mL.
Among samples with detectable HIVRNA, the correlation between viral load values obtained from the paired 131 plasma and DBS samples was high (Pearson correlation coefficient 0.946 and R 2 =0.895) (Fig. 1) . The mean (SD) difference between the measured viral load in DBS and in plasma was 0.15 (0.27) log copies/mL. HIVRNA levels obtained from DBS were higher than in plasma in 70.2% of the samples. However, this overquantification was observed mainly in specimens with a plasma viral load of <3 000 copies/mL (mean (SD) difference 0.38 (0.19)), while the difference for samples with a plasma viral load of >3 000 copies/mL was negligible (0.09 (0.26)). Overall, viral load values between DBS and plasma differed by <0.5 log unit in 90.1% of cases and by <1 log unit in 100%.
Agreement between the two methods was calculated by the Bland Altman method, [8] in which the differences between individual viral load results from plasma and DBS are plotted against the mean of the two results. In Fig. 2 it can be seen that the data are well scattered over the mean along the overall range of viral load examined and that all but five samples were within the 1.96 SD limits, underlining the good agreement between the two methods. The detection rate with DBS was 90.1% when plasma levels were >1 000 copies/mL. Categorising the samples according to this 1 000 copies/ mL threshold, of the 138 samples with a viral load of >1 000 copies/mL, 8 (5.8%) had a DBS viral load of <1 000 copies/ ml and therefore would have been missed if the virological failure threshold had been set at 1 000 copies/mL. Of the 139 samples with a plasma viral load of <1 000 copies/mL, only 2 (1.4%) had an HIV RNA in DBS of >1 000 copies/ml and could represent false virological failure detection. With the threshold of 1 000 copies/mL, sensitivity was 94.2%, specificity 98.6% and positive and negative predictive values 98.5% and 94.5%, respectively ( Table 1 ). The agreement between DBS and plasma HIVRNA quanti fication at the 1 000 copies/mL threshold was high, as demon strated by the Kappa coefficient value of 0.928 (standard error 0.022, p<0.001).
Discussion
Several reports have been published on the use of DBS for viral load quantification using different methodologies, including the Abbott assay. [9] In the great majority of cases the results were comparable with those obtained from plasma. However, the use of DBS collected and prepared in realworld conditions for viral load monitoring with the automated Abbott assay has been reported in only a few studies. [1012] Our data, obtained from DBS collected and processed by local personnel in Malawi and Mozambique, showed that DBS gave comparable results in respect of the reference method in the range from 3 to 7 logs copies/ mL. However, the detection rate below the threshold of 1 000 copies/mL was lower, as reported in other articles, [2, 13] although the lowest plasma RNA value at which DBS RNA was detectable was 616 copies/mL in line with the threshold of 550 copies/mL previously reported for this assay. [5] The modest overquantification that we observed with DBS can be ascribed to the presence of HIVDNA and intracellular RNA and seems to have a greater impact on samples with a low viral load (in our study <3 000 copies/mL), as previously reported. [4, 11, 14] The 2013 HIV treatment guidelines of the World Health Organi zation [15] indicate a threshold of 1 000 copies/mL of HIVRNA to define virological failure using plasma, and suggest use of a higher, although undefined, threshold when using DBS. In previous studies performed with the Abbott system, sensitivity for the detection of virological failure at 1 000 copies/mL was between 75% and 100% and specificity was between 82% and 97%. [10, 11] In our study, very high positive and negative predictive values were observed when using a threshold of 1 000 copies/mL, suggesting that even with the use of DBS the threshold of 1 000 copies/mL can provide reliable results, given the specificity of 98.6% at this threshold.
The last systematic review of the use of DBS for monitoring HIV viral load [9] emphasised the need for a standardised approach for sampling, storing and processing DBS samples in order to establish whether DBS could reliably replace plasma specimens to identify virological failure. Our study suggests that DBS on filter paper, stored at room temperature and processed with an automated extractor, followed by realtime quantification of HIVRNA, could represent a standard to be applied in resourcelimited settings.
Conclusion
Our study demonstrated that HIV1 quantification from DBS using a standardised commercial assay provides reliable identification of virological failure in SSA. 
